JP2023518635A5 - - Google Patents

Info

Publication number
JP2023518635A5
JP2023518635A5 JP2022538393A JP2022538393A JP2023518635A5 JP 2023518635 A5 JP2023518635 A5 JP 2023518635A5 JP 2022538393 A JP2022538393 A JP 2022538393A JP 2022538393 A JP2022538393 A JP 2022538393A JP 2023518635 A5 JP2023518635 A5 JP 2023518635A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
brain
nac
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518635A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/066179 external-priority patent/WO2021127541A1/en
Publication of JP2023518635A publication Critical patent/JP2023518635A/ja
Publication of JP2023518635A5 publication Critical patent/JP2023518635A5/ja
Pending legal-status Critical Current

Links

JP2022538393A 2019-12-18 2020-12-18 脳障害を処置する方法 Pending JP2023518635A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962949640P 2019-12-18 2019-12-18
US62/949,640 2019-12-18
US202062970254P 2020-02-05 2020-02-05
US62/970,254 2020-02-05
PCT/US2020/066179 WO2021127541A1 (en) 2019-12-18 2020-12-18 Methods of treating brain disorders

Publications (2)

Publication Number Publication Date
JP2023518635A JP2023518635A (ja) 2023-05-08
JP2023518635A5 true JP2023518635A5 (https=) 2024-07-03

Family

ID=76437600

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538393A Pending JP2023518635A (ja) 2019-12-18 2020-12-18 脳障害を処置する方法

Country Status (7)

Country Link
US (3) US12090130B2 (https=)
EP (1) EP4076425A1 (https=)
JP (1) JP2023518635A (https=)
CN (1) CN115484945A (https=)
AU (1) AU2020407239B2 (https=)
CA (1) CA3165422A1 (https=)
WO (1) WO2021127541A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020380291A1 (en) * 2019-11-04 2022-05-26 Neuronasal, Inc. Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of N-acetylcysteine
CA3165422A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders
WO2022067232A1 (en) * 2020-09-28 2022-03-31 Commercial Automation, Llc Food product storage and vending kiosk
CA3193558A1 (en) * 2020-10-01 2022-04-07 Lyra Therapeutics, Inc. Osmotic drug delivery implants
US12594254B2 (en) * 2022-02-07 2026-04-07 Neuronasal, Inc. Intranasal administration of n-acetylcysteine and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
EP2749552B1 (en) 2007-04-17 2015-11-18 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
CA2871774C (en) 2012-04-26 2021-05-18 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
ES2844199T3 (es) 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
BR112017025499A2 (pt) 2015-05-28 2018-08-07 Baylor College Medicine benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa
EP3618824A4 (en) * 2017-05-02 2021-06-23 Neuronasal, LLC USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
WO2019084543A1 (en) 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS
CA3165422A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders

Similar Documents

Publication Publication Date Title
JP2023518635A5 (https=)
CA2838529C (en) Methods of treatment
JP2023500360A5 (https=)
JP2023507094A5 (https=)
JP2019520361A5 (https=)
JP2008536546A5 (https=)
RU2005135335A (ru) Назальные фармацевтические композиции и способы их применения
JP2014516081A5 (https=)
BR0311558A (pt) composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica
FI4106757T3 (fi) Neutrofiilien elastaasin inhibiittori alvelestaattia sisältäviä menetelmiä alfa-1-antitrypsiinipuutoksen välittämän hengityselintaudin hoitamiseksi
JP2021152060A (ja) アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
EA022840B1 (ru) Фармацевтическая композиция, набор, их применение и способ профилактики и лечения симптома, состояния или заболевания, связанного с инфекцией вируса гриппа
HRP20192111T1 (hr) Liječenje poremećaja središnjeg živčanog sustava intranazalnom primjenom imunoglobulina g
JP2022512704A5 (https=)
US20230263725A1 (en) Intranasal administration of an antioxidant compound for treating coronavirus infection
BRPI0409434A (pt) formulações farmacêuticas nasais e métodos para usar as mesmas
EP1201236A4 (en) MEDICAL COMPOSITIONS FOR PREVENTING THE TREATMENT OF VIRAL MYOCASCHITIS
JP2022535920A5 (https=)
RU2011101771A (ru) Педиатрические композиции для лечения рассеянного склероза
JP2023520703A5 (https=)
JP2020531586A5 (https=)
WO2021205026A3 (en) Pharmaceutical composition for treatment of enveloped dna or rna virus induced infections and disorders
CN108472375A (zh) 中重度流感的治疗方法
EA202190724A1 (ru) Препарат на основе кетамина для лечения депрессий путём ингаляций
Pooja et al. A Review: Nasopulmonary Drug Delivery System